Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 12, 2011, Pages 1945-1958

  Filippatos, Theodosios D ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cardiovascular risk; Cholesterol; Fenofibrate; High density lipoprotein; Inflammation; Simvastatin; Triglycerides

Indexed keywords

FENOFIBRATE; FENOFIBRATE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLECYSTITIS; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROESOPHAGEAL REFLUX; HUMAN; LIVER FUNCTION TEST; MONOTHERAPY; MUSCULOSKELETAL PAIN; MYALGIA; MYOPATHY; NAUSEA; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DRUG COMBINATIONS; DRUG MONITORING; DYSLIPIDEMIAS; FENOFIBRATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS; RISK FACTORS; SIMVASTATIN;

EID: 79960441327     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.593509     Document Type: Review

References (140)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines. J Am Coll Cardiol 2004;44:720-32
3. Delahoy PJ, Magliano DJ, Webb K, et al. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther 2009;31:236-44
4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
5. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. QJM 2011;104:109-24
6. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793-802 (Pubitemid 29379144)
7. Horiuchi H, Kita T, Mabuchi H, et al. Primary cardiovascular events and serum lipid levels in elderly Japanese with hypercholesterolemia undergoing 6-year simvastatin treatment: a subanalysis of the Japan lipid intervention trial. J Am Geriatr Soc 2004;52:1981-7 (Pubitemid 41725012)
8. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J 2006;151:273-81 (Pubitemid 43144726)
9. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
10. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
11. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007;45:645-54
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
13. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211-18 (Pubitemid 28007446)
14. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93:1796-802
15. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996;156:2085-92
16. Florentin M, Liberopoulos EN, Moutzouri E, et al. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin 2011;27:685-92
17. Chan SY, Mancini GB, Ignaszewski A, Frohlich J. Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study. BMC Clin Pharmacol 2008;8:10
18. Miller M, Dobs A, Yuan Z, et al. The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study. Curr Med Res Opin 2006;22:343-50 (Pubitemid 44296758)
19. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Effects of long-term treatment with simvastatin on some hemostatic parameters in continuous ambulatory peritoneal dialysis patients. Am J Nephrol 2001;21:373-7 (Pubitemid 34701842)
20. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Influence of simvastatin on aspects of thrombogenesis in CAPD patients. Perit Dial Int 2003;23:260-6 (Pubitemid 37045663)
21. Medina RJ, O'Neill CL, Devine AB, et al. The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS One 2008;3:e2584
22. Ukinc K, Ersoz HO, Erem C, et al. Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients. Endocrine 2009;35:380-8
23. Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and non-vascular mortality. J Intern Med 2010;268:348-58
24. Qiao Z, Ren J, Chen H. Simvastatin reduces expression and activity of lipoprotein-associated phospholipase A(2) in the aorta of hypercholesterolaemic atherosclerotic rabbits. J Int Med Res 2009;37:1029-37
25. Wei-hua L, Chang-qing S, Qiang X, et al. Simvastatin inhibits sPLA2 IIa expression in aorta and myocardium. Arch Med Res 2009;40:67-72
26. Iwase M, Sonoki K, Sasaki N, et al. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis 2008;196:931-6
27. Koh KK, Quon MJ, Sakuma I, et al. Effects of simvastatin therapy on circulating adipocytokines in patients with hypercholesterolemia. Int J Cardiol 2011;146:434-7
28. Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 2011;215:1-8
29. Krysiak R, Gdula-Dymek A, Scieszka J, Okopien B. Anti-inflammatory and monocyte-suppressing effects of simvastatin in patients with impaired fasting glucose. Basic Clin Pharmacol Toxicol 2011;108:131-7
30. Krysiak R, Okopien B. Lymphocyte-suppressing effect of simvastatin in mixed dyslipidemic patients but not impaired glucose tolerance patients. Pharmacol Rep 2011;63:95-101
31. Krysiak R, Gdula-Dymek A, Okopien B. Hemostatic effects of simvastatin in subjects with impaired fasting glucose. Pharmacol Rep 2010;62:1090-8
32. Moohebati M, Bidmeshgi S, Azarpazhooh MR, et al. Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: A randomized, double-blind, placebo-controlled, cross-over trial. Clin Biochem 2011;44:192-7
33. Kaczmarek P, Sladek K, Skucha W, et al. The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease. Pol Arch Med Wewn 2010;120:11-17
34. Undas A, Siudak Z, Topor-Madry R, et al. Simvastatin administration reduces thromboxane production in subjects taking aspirin: links between aspirin resistance and thrombin generation. Int J Cardiol 2010 (In press)
35. Panichi V, Paoletti S, Mantuano E, et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 2006;21:337-44 (Pubitemid 43159986)
36. Milionis HJ, Papakostas J, Kakafika A, et al. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 2003;43:825-30 (Pubitemid 36886102)
37. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25
38. Hermans MP, Castro Cabezas M, Strandberg T, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin 2010;26:445-54
39. Elisaf MS, Nikas N. Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs-the CEPHEUS-Greece survey. Angiology 2010;61:465-74
40. da Silva PM, Cardoso SM. Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS). Rev Port Cardiol 2011;30:47-63
41. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376:1658-69
42. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010;105:69-76
43. Alsheikh-Ali AA, Lin JL, Abourjaily P, et al. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol 2007;100:1499-501 (Pubitemid 350050854)
44. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-8 (Pubitemid 46184196)
45. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009;1791:327-38
46. Gazi IF, Tsimihodimos V, Tselepis AD, et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007;7:53-72 (Pubitemid 46091576)
47. Hingorani AD, Shah T, Casas JP, et al. C-reactive protein and coronary heart disease: predictive test or therapeutic target? Clin Chem 2009;55:239-55
48. Filippatos TD, Tsimihodimos V, Kostapanos M, et al. Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome. Arch Med Sci 2008;4:263-9
49. Seifalian AM, Filippatos TD, Joshi J, Mikhailidis DP. Obesity and arterial compliance alterations. Curr Vasc Pharmacol 2010;8:155-68
50. Nakou ES, Filippatos TD, Agouridis AP, et al. The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids 2010;45:445-50
51. Agouridis AP, Filippatos TD, Tsimihodimos V, Elisaf MS. Combinations of ezetimibe with non-statin drug regimens affecting lipid metabolism. Expert Rev Cardiovasc Ther 2011;9:355-66
52. Rizzo M, Rini GB, Berneis K. Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. Adv Ther 2007;24:575-82 (Pubitemid 47295434)
53. Agouridis AP, Tsimihodimos V, Filippatos TD, et al. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids 2011;46:521-8
54. Ai M, Otokozawa S, Asztalos BF, et al. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol 2008;101:315-18 (Pubitemid 351175627)
55. Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007;23:1169-76 (Pubitemid 46799601)
56. Kostapanos MS, Milionis HJ, Filippatos TD, et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther 2007;29:1403-14 (Pubitemid 47348117)
57. Florentin M, Tselepis AD, Elisaf MS, et al. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Curr Vasc Pharmacol 2010;8:820-30
58. Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des 2009;15:490-516
59. Filippatos T, Derdemezis C, Elisaf M. Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors. Clin Lipidol 2009;4:331-41
60. Tzotzas T, Filippatos TD, Triantos A, et al. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Nutr Metab Cardiovasc Dis 2008;18:477-82
61. Nakou E, Filippatos TD, Liberopoulos EN, et al. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharmacother 2008;9:1629-39
62. Nakou ES, Filippatos TD, Georgoula M, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 2008;24:1919-29
63. Nakou ES, Filippatos TD, Kiortsis DN, et al. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother 2008;9:3151-8
64. Filippatos T, Milionis HJ. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs 2008;17:1599-614
65. Agouridis AP, Filippatos TD, Derdemezis CS, et al. Combination of fenofibrate with non-statin drug regimens. Curr Pharm Des 2010;16:3401-16
66. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005;11:4161-75 (Pubitemid 41679180)
67. Tsimihodimos V, Miltiadous G, Daskalopoulou SS, et al. Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol 2005;3:87-98 (Pubitemid 40089531)
68. Uetake D, Ohno I, Ichida K, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med 2010;49:89-94
69. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-27 (Pubitemid 46050336)
70. Winkler K, Schewe T, Putz G, et al. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur J Clin Invest 2009;39:463-70
71. May HT, Anderson JL, Pearson RR, et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen Study). Am J Cardiol 2008;101:486-9 (Pubitemid 351199437)
72. Tribble DL, Farnier M, Macdonell G, et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 2008;57:796-801 (Pubitemid 351697911)
73. Rizzo M, Berneis K. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Curr Med Res Opin 2007;23:1103-11 (Pubitemid 46799594)
74. Farnier M, Perevozskaya I, Taggart WV, et al. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J Lipid Res 2008;49:2641-7
75. Tsimihodimos V, Liberopoulos E, Elisaf M. Pleiotropic effects of fenofibrate. Curr Pharm Des 2009;15:517-28
76. Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 2010;95:829-36
77. Wu TJ, Ou HY, Chou CW, et al. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate. Ann Clin Lab Sci 2007;37:158-66
78. Hiukka A, Leinon-en E, Jauhiainen M, et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 2007;50:2067-75 (Pubitemid 47373844)
79. Chan DC, Watts GF, Ooi EM, et al. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1831-7
80. Hamilton SJ, Chew GT, Davis TM, Watts GF. Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients. Clin Sci (Lond) 2010;118:607-15
81. Genest J Jr, Nguyen NH, Theroux P, et al. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. J Cardiovasc Pharmacol 2000;35:164-72 (Pubitemid 30032909)
82. Filippatos T, Tsimihodimos V, Kostapanos M, et al. Analysis of the 6-month effect of orlistat, alone or in combination with fenofibrate, administration on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. J Clin Lipidol 2008;2:279-84
83. Rosenson RS. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring) 2009;17:504-9
84. Filippatos TD, Liberopoulos EN, Kostapanos M, et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 2008;10:476-83 (Pubitemid 351639090)
85. Florentin M, Liberopoulos EN, Filippatos TD, et al. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opin Pharmacother 2008;9:2741-50
86. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007;193:428-37 (Pubitemid 47058108)
87. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005;21:1997-2006 (Pubitemid 41803111)
88. Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493-8
89. Sacks FM. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Am J Cardiol 2008;102:34L-40L
90. Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009;373:1780-8
91. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97 (Pubitemid 350100775)
92. Fievet C, Staels B. Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr Opin Lipidol 2009;20:505-11
93. Moutzouri E, Kei A, Elisaf MS, Milionis HJ. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag 2010;6:525-39
94. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Statin-fibrate combination for mixed dyslipidaemia: a limited option? Curr Med Res Opin 2010;26:2137-40
95. Pedersen TR, Tobert JA. Simvastatin: a review. Expert Opin Pharmacother 2004;5:2583-96 (Pubitemid 39646520)
96. Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004;44:1054-62 (Pubitemid 39096820)
97. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006;48:396-401
98. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein (a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007;27:2094-9 (Pubitemid 350287235)
99. Gazi I, Lourida ES, Filippatos T, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005;51:2264-73 (Pubitemid 41692569)
100. Elisaf M, Tselepis AD. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol 2003;66:2069-73 (Pubitemid 37377852)
101. Reddy KJ, Singh M, Batsell RR, et al. Effects of lifestyle counseling and combination lipid-modifying therapy on lipoprotein-associated phospholipase A2 mass concentration. J Clin Lipidol 2009;3:275-80
102. Saougos VG, Tambaki AP, Kalogirou M, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007;27:2236-43 (Pubitemid 350287255)
103. Rizos CV, Liberopoulos EN, Tellis CC, et al. Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-gamma activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A (2). Metab Syndr Relat Disord 2011;9:217-23
104. Tsimihodimos V, Kakafika A, Tambaki AP, et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 2003;44:927-34 (Pubitemid 37279653)
105. Rosenson RS. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am Heart J 2008;155:499, e9-16
106. Miyazaki T, Shimada K, Miyauchi K, et al. Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting. Lipids Health Dis 2010;9:122
107. Ikewaki K, Tohyama J, Nakata Y, et al. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men-a nuclear magnetic resonance study. J Atheroscler Thromb 2004;11:278-85
108. Krysiak R, Gdula-Dymek A, Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol 2011;107:1010-18, e1
109. Kayikcioglu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol 1999;83:1135-7 (Pubitemid 29162807)
110. Wierzbicki AS, Lumb PJ, Cheung J, Crook MA. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia. QJM 1997;90:631-4 (Pubitemid 27453827)
111. Derosa G, Maffioli P, Salvadeo SA, et al. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin 2009;25:1973-83
112. Bramlett HM, Dietrich WD. Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J Cereb Blood Flow Metab 2004;24:133-50 (Pubitemid 38199107)
113. Besson VC, Chen XR, Plotkine M, Marchand-Verrecchia C. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury. Neurosci Lett 2005;388:7-12 (Pubitemid 41569361)
114. Chen XR, Besson VC, Palmier B, et al. Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma 2007;24:1119-31 (Pubitemid 47106286)
115. Paumelle R, Blanquart C, Briand O, et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 2006;98:361-9
116. Chen XR, Besson VC, Beziaud T, et al. Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury. J Pharmacol Exp Ther 2008;326:966-74
117. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95:462-8 (Pubitemid 40247539)
118. Grundy SM, Vega GL, Tomassini JE, Tershakovec AM. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). Am J Cardiol 2009;104:548-53
119. Stefanutti C, Bucci A, Di Giacomo S, et al. Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia. Clin Drug Investig 2004;24:465-77 (Pubitemid 39128013)
120. Buse JB, Bigger JT, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99:21i-33i
121. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
122. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37-45
123. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7
124. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-84
125. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010;363:692-4
126. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18 (Pubitemid 29362514)
127. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162:2597-604 (Pubitemid 35453499)
128. Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154-60 (Pubitemid 40720740)
129. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45 (Pubitemid 17147964)
130. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44
131. Franssen R, Vergeer M, Stroes ES, Kastelein JJ. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab 2009;11:89-94
132. Taher TH, Dzavik V, Reteff EM, et al. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol 2002;89:390-4 (Pubitemid 34142511)
133. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90 (Pubitemid 37430274)
134. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95:120-2 (Pubitemid 40051126)
135. Tsimihodimos V, Kakafika A, Elisaf M. Fibrate treatment can increase serum creatinine levels. Nephrol Dial Transplant 2001;16:1301 (Pubitemid 32547398)
136. Tsimihodimos V, Bairaktari E, Elisaf M. Fibrate-induced increase in serum urea and creatinine levels. Nephrol Dial Transplant 2002;17:682 (Pubitemid 34308831)
137. Tsimihodimos V, Miltiadous G, Bairaktari E, Elisaf M. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol 2002;57:407-8
138. Forsblom C, Hiukka A, Leinon-en ES, et al. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care 2010;33:215-20
139. Hottelart C, El Esper N, Rose F, et al. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002;92:536-41
140. Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998;81:60B-5B (Pubitemid 28113948)